ATE423104T1 - Quinazolin derivate als antitumor-mittel - Google Patents

Quinazolin derivate als antitumor-mittel

Info

Publication number
ATE423104T1
ATE423104T1 AT02774960T AT02774960T ATE423104T1 AT E423104 T1 ATE423104 T1 AT E423104T1 AT 02774960 T AT02774960 T AT 02774960T AT 02774960 T AT02774960 T AT 02774960T AT E423104 T1 ATE423104 T1 AT E423104T1
Authority
AT
Austria
Prior art keywords
tumor agent
quinazoline derivatives
quinazoline
derivatives
tumor
Prior art date
Application number
AT02774960T
Other languages
English (en)
Inventor
Laurent Hennequin
Jason Kettle
Martin Pass
Robert Bradbury
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0126433.2A external-priority patent/GB0126433D0/en
Priority claimed from GB0129059A external-priority patent/GB0129059D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE423104T1 publication Critical patent/ATE423104T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT02774960T 2001-11-03 2002-10-31 Quinazolin derivate als antitumor-mittel ATE423104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126433.2A GB0126433D0 (en) 2001-11-03 2001-11-03 Compounds
GB0129059A GB0129059D0 (en) 2001-12-05 2001-12-05 Compounds

Publications (1)

Publication Number Publication Date
ATE423104T1 true ATE423104T1 (de) 2009-03-15

Family

ID=26246737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774960T ATE423104T1 (de) 2001-11-03 2002-10-31 Quinazolin derivate als antitumor-mittel

Country Status (23)

Country Link
US (2) US20050043336A1 (de)
EP (1) EP1444210B1 (de)
JP (1) JP2005515176A (de)
KR (1) KR20050042055A (de)
CN (1) CN100343238C (de)
AR (1) AR037330A1 (de)
AT (1) ATE423104T1 (de)
BR (1) BR0213842A (de)
CA (1) CA2465068A1 (de)
CO (1) CO5580774A2 (de)
DE (1) DE60231230D1 (de)
ES (1) ES2320980T3 (de)
HK (1) HK1066218A1 (de)
HU (1) HUP0401646A2 (de)
IL (1) IL161619A0 (de)
IS (1) IS7240A (de)
MX (1) MXPA04004219A (de)
NO (1) NO20042279L (de)
NZ (1) NZ532524A (de)
PL (1) PL369938A1 (de)
RU (1) RU2004116911A (de)
TW (1) TW200301702A (de)
WO (1) WO2003040108A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002245709A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
HN2002000067A (es) * 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR101093345B1 (ko) * 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
WO2004056812A1 (en) * 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
US7262293B2 (en) * 2003-07-02 2007-08-28 Corus Pharma Aztreonam L-lysine and methods for the preparation thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA06001767A (es) 2003-08-14 2006-05-12 Array Biopharma Inc Analogos de quinazolina como inhibidores de la tirosina quinasa receptora.
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
EP1667996B1 (de) * 2003-09-16 2009-07-22 Astrazeneca AB Chinazolinderivate
RU2378268C2 (ru) * 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20050197371A1 (en) * 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MXPA06008293A (es) 2004-01-22 2007-06-11 Univ Miami Formulaciones topicas de coenzima q10 y metodos de uso.
EP1711495A2 (de) 2004-01-23 2006-10-18 Amgen Inc. Chinolin-, chinazolin-, pyridin- und pyrimidinverbindungen und deren verwendung bei der behandlung von entzündungen, angiogenese und krebs
BRPI0507373A (pt) 2004-01-23 2007-07-10 Amgen Inc compostos e método de uso
EP1713781B1 (de) * 2004-02-03 2008-11-05 AstraZeneca AB Chinazolinderivate
FR2866887A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-heteroaryle, compositon tinctoriale comprenant une telle para-phenylenediamine, procede mettant en oeuvre cette composition et utilisation
KR100885835B1 (ko) 2004-05-06 2009-02-26 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
JP2008501675A (ja) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Ｅｒｂｂ受容体型チロシンキナーゼとしてのキナゾリン誘導体
US7659284B2 (en) 2004-09-15 2010-02-09 Janssen Pharmaceutica Nv Thiazolopyridine kinase inhibitors
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
EP1828152B1 (de) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
WO2006064196A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Pyrazolopyrimidine compounds as antitumor agents
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
GB0504475D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
WO2007034144A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
EP1940825A1 (de) * 2005-09-20 2008-07-09 Astra Zeneca AB Chinazolinderivat als antikrebsmittel
BR122018075851B1 (pt) 2005-11-15 2022-01-11 Array Biopharma Inc Compostos relacionados ao tratamento de doença hiperproliferativa e processos para preparar compostos
EP1960371B1 (de) * 2005-12-02 2009-09-16 AstraZeneca AB Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
EP1957499A1 (de) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilinosubstituierte chinazolinderivate als tyrosinkinaseinhibitoren
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JP2009544609A (ja) * 2006-07-18 2009-12-17 アストラゼネカ・アクチエボラーグ 置換２−アセチルアミノ−アルコキシフェニルの製造方法
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP2137177B1 (de) * 2007-04-05 2014-05-07 Amgen, Inc Aurora-kinasemodulatoren und verwendungsverfahren
EP2220078B1 (de) * 2007-10-29 2013-05-22 Amgen, Inc Benzomorpholinderivate und anwendungsverfahren
JP2011502141A (ja) 2007-10-29 2011-01-20 ナトコ ファーマ リミテッド 抗癌剤としての４‐（テトラゾール‐５‐イル）‐キナゾリン誘導体
AU2009211523B2 (en) 2008-02-07 2014-03-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
KR20100136997A (ko) 2008-04-11 2010-12-29 싸이토테크 랩스, 엘엘씨 암세포에서 아폽토시스를 유도하는 방법 및 용도
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
MX2011011958A (es) 2009-05-11 2012-02-13 Berg Biosystems Llc Metodos para el tratamiento de trastornos metabolicos utilizando cambiadores epimetabólicos, moléculas intracelulares multidimensionales o influenciadores ambientales.
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
EP2983654A4 (de) 2013-04-08 2016-11-30 Berg Llc Behandlung von krebs mit coenzym-q10-kombinationstherapien
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3071204B1 (de) 2013-11-20 2019-02-20 SignalChem Lifesciences Corp. Chinazolinderivate als kinaseinhibitoren der tam-familie
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
CN106831599B (zh) * 2017-03-03 2019-08-23 南京理工大学 一种合成1-二氟甲基咪唑及其衍生物的方法
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
AR117424A1 (es) 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb
EP3853220B1 (de) * 2018-09-18 2024-01-03 F. Hoffmann-La Roche AG Chinoxalinderivate als wirkstoffe gegen tumoren
CN109336828B (zh) * 2018-11-30 2022-04-26 雅安职业技术学院 一种喹唑啉衍生物及其制备方法和应用
CN113200945A (zh) * 2021-04-23 2021-08-03 上海应用技术大学 一种芳香胺化合物的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
MX9707487A (es) * 1996-01-31 1997-11-29 Gist Brocades Bv Uso de composiciones que comprenden compuestos efectivos biologicamente estabilizados.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ATE227283T1 (de) * 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003031406A2 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
KR20060054388A (ko) * 2003-07-29 2006-05-22 아스트라제네카 아베 티로신 키나아제 억제제로서의 피페리딜-퀴나졸린 유도체
EP1667996B1 (de) * 2003-09-16 2009-07-22 Astrazeneca AB Chinazolinderivate
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
RU2378268C2 (ru) * 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
WO2005030757A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (de) * 2004-02-03 2008-11-05 AstraZeneca AB Chinazolinderivate
JP2008501675A (ja) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Ｅｒｂｂ受容体型チロシンキナーゼとしてのキナゾリン誘導体

Also Published As

Publication number Publication date
BR0213842A (pt) 2004-08-31
KR20050042055A (ko) 2005-05-04
HK1066218A1 (en) 2005-03-18
EP1444210B1 (de) 2009-02-18
CA2465068A1 (en) 2003-05-15
EP1444210A1 (de) 2004-08-11
WO2003040108A1 (en) 2003-05-15
IS7240A (is) 2004-04-30
AR037330A1 (es) 2004-11-03
TW200301702A (en) 2003-07-16
CN1585754A (zh) 2005-02-23
HUP0401646A2 (hu) 2004-12-28
PL369938A1 (en) 2005-05-02
DE60231230D1 (de) 2009-04-02
US20070082921A1 (en) 2007-04-12
NZ532524A (en) 2007-02-23
US20050043336A1 (en) 2005-02-24
NO20042279L (no) 2004-06-02
CO5580774A2 (es) 2005-11-30
MXPA04004219A (es) 2004-09-10
ES2320980T3 (es) 2009-06-01
JP2005515176A (ja) 2005-05-26
IL161619A0 (en) 2004-09-27
RU2004116911A (ru) 2005-11-10
CN100343238C (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
ATE423104T1 (de) Quinazolin derivate als antitumor-mittel
ATE421507T1 (de) Quinazolin derivate als antitumor-mittel
ATE450528T1 (de) Chinazolinderivate als antitumormittel
DK1847539T3 (da) Quinazolin-derivater
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
ATE512965T1 (de) Pyrrolopyrimidin derivate
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
IS7328A (is) Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
IS7362A (is) Kínasólín efnasambönd
DE60233335D1 (de) Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
DE602004022180D1 (de) Chinazolinderivate
DE602004004553D1 (de) Chinazolinderivate
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
EE200300071A (et) Kinasoliini derivaadid
DE60207815D1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
IL164135A0 (en) 4-Anilino quinazoline derivatives as antirpoliferative agents
ATE376549T1 (de) Pyrrolopyridazin derivate
ATE273980T1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE309225T1 (de) Substituierte chinazoline derivate
NO20035573D0 (no) Kinazolinderivater
DE60215804D1 (de) 4-aminopyrimidine derivate
ATE496034T1 (de) Phtalazinon derivate
ATE269316T1 (de) 2-phenylpyran-4-on derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties